help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2002-0190
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshikawa, T.
Right arrow Articles by Yamada, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshikawa, T.
Right arrow Articles by Yamada, N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Molecular Endocrinology 17 (7): 1240-1254
Copyright © 2003 by The Endocrine Society

Cross-Talk between Peroxisome Proliferator-Activated Receptor (PPAR) {alpha} and Liver X Receptor (LXR) in Nutritional Regulation of Fatty Acid Metabolism. I. PPARs Suppress Sterol Regulatory Element Binding Protein-1c Promoter through Inhibition of LXR Signaling

Tomohiro Yoshikawa, Tomohiro Ide, Hitoshi Shimano, Naoya Yahagi, Michiyo Amemiya-Kudo, Takashi Matsuzaka, Shigeru Yatoh, Tetsuya Kitamine, Hiroaki Okazaki, Yoshiaki Tamura, Motohiro Sekiya, Akimitsu Takahashi, Alyssa H. Hasty, Ryuichiro Sato, Hirohito Sone, Jun-ichi Osuga, Shun Ishibashi and Nobuhiro Yamada

Department of Metabolic Diseases (T.Y., N.Y., M.A.-K., T.K., H.O., Y.T., M.S., A.H.H., J.O., S.I.), Faculty of Medicine, Department of Applied Biological Chemistry (R.S.), Graduate School of Agricultural and Life Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan; and Department of Internal Medicine (T.I., H.S., T.M., S.Y., A.T., H.S., N.Y.), Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8575, Japan

Address all correspondence and requests for reprints to: Hitoshi Shimano, M.D., Ph.D., Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Ibaraki 305-8575, Japan. E-mail: shimano-tky{at}umin.ac.jp.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Liver X receptors (LXRs) and peroxisome proliferator-activated receptors (PPARs) are members of nuclear receptors that form obligate heterodimers with retinoid X receptors (RXRs). These nuclear receptors play crucial roles in the regulation of fatty acid metabolism: LXRs activate expression of sterol regulatory element-binding protein 1c (SREBP-1c), a dominant lipogenic gene regulator, whereas PPAR{alpha} promotes fatty acid ß-oxidation genes. In the current study, effects of PPARs on the LXR-SREBP-1c pathway were investigated. Luciferase assays in human embryonic kidney 293 cells showed that overexpression of PPAR{alpha} and {gamma} dose-dependently inhibited SREBP-1c promoter activity induced by LXR. Deletion and mutation studies demonstrated that the two LXR response elements (LXREs) in the SREBP-1c promoter region are responsible for this inhibitory effect of PPARs. Gel shift assays indicated that PPARs reduce binding of LXR/RXR to LXRE. PPAR{alpha}-selective agonist enhanced these inhibitory effects. Supplementation with RXR attenuated these inhibitions by PPARs in luciferase and gel shift assays, implicating receptor interaction among LXR, PPAR, and RXR as a plausible mechanism. Competition of PPAR{alpha} ligand with LXR ligand was observed in LXR/RXR binding to LXRE in gel shift assay, in LXR/RXR formation in nuclear extracts by coimmunoprecipitation, and in gene expression of SREBP-1c by Northern blot analysis of rat primary hepatocytes and mouse liver RNA. These data suggest that PPAR{alpha} activation can suppress LXR-SREBP-1c pathway through reduction of LXR/RXR formation, proposing a novel transcription factor cross-talk between LXR and PPAR{alpha} in hepatic lipid homeostasis.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
STEROL REGULATORY ELEMENT (SRE)-binding proteins (SREBPs) are membrane-bound transcription factors that belong to the basic helix-loop-helix leucine zipper family (1, 2, 3). Through sterol-regulated cleavage, SREBP enters the nucleus and activates the transcription of genes involved in cholesterol and fatty acid synthesis by binding to a SRE or its related sequences including SRE-like sequences and E-boxes, within their promoter regions (4, 5). There are three forms of SREBP: SREBP-1a and -1c (also known as adipocyte determination and differentiation 1, ADD1) and -2 (6, 7, 8). Most organs, including the liver and adipose tissue, express predominantly SREBP-2 and the -1c isoform of SREBP-1 (9). Recent in vivo studies demonstrated that SREBP-1c plays a crucial role in the dietary regulation of most hepatic lipogenic genes, whereas SREBP-2 is actively involved in the transcription of cholesterogenic enzymes (10, 11, 12, 13, 14, 15, 16, 17). SREBP-1c seems to control hepatic lipogenic enzymes through changing its mRNA level in a process that appears to be highly related to glucose/insulin signaling (18).

Liver X receptors (LXRs) belong to a subclass of nuclear hormone receptors that form obligate heterodimers with retinoid X receptors (RXR) and are activated by oxysterols (19, 20, 21, 22). There have been two subtypes of LXRs identified: LXR{alpha} and LXRß. LXR{alpha} is expressed in liver, spleen, kidney, adipose, and small intestine (23), whereas LXRß is ubiquitously expressed (24). LXRs have been established to regulate intracellular cholesterol levels by transactivating the expression of cholesterol 7{alpha}-hydroxylase (21, 22, 25), cholesterol ester transfer protein (26), and ATP-binding cassette transporter A1 (ABCA1), which modulates cholesterol efflux and mediates reverse cholesterol transport from peripheral tissues. LXR/RXR also appears to be involved in cholesterol absorption in intestine (27). Furthermore, LXR/RXR was recently identified as a dominant activator of SREBP-1c promoter (28, 29), implicating a new link between cholesterol and fatty acid metabolism.

Peroxisome proliferator-activated receptors (PPARs) belong to a ligand-activated nuclear hormone receptor superfamily and are known to regulate the expression of numerous genes involved in fatty acid metabolism and adipocyte differentiation (30, 31). PPAR{alpha} is primarily expressed in the liver, in which it has been shown to promote ß-oxidation of fatty acids (30). PPAR{gamma} is mainly expressed in adipose tissue (32), where it has been shown to be an essential component of the adipocyte differentiation program (33); and in macrophages, where it modulates differentiation and cytokine production (34, 35, 36). PPARs were originally identified as factors that mediate transcriptional responses to peroxisome proliferators, a broad class of xenobiotic chemicals that include fibrate hypolipidemic drugs and other nongenotoxic rodent hepatocarcinogens (37, 38). Subsequently, PPARs were shown to be differentially activated by a variety of saturated or unsaturated long chain fatty acids and lipid-like compounds (39, 40, 41, 42, 43), suggesting that fatty acids or fatty acid derivatives serve as physiological activators.

The roles of these nutritional transcription factors in whole body physiology and metabolism can be best illustrated by comparing two opposite nutritional states: fasted and refed states. In the fasted liver, fatty acids are oxidized to acetyl-coenzyme A (CoA) and subsequently to ketone bodies. PPAR{alpha}, plays a major role in both processes, which was confirmed by observations in PPAR{alpha}-null mice (44, 45). In contrast, expression of SREBP-1c is reduced during fasting. In the refed state, lipogenesis is induced through increased amount of SREBP-1, whereas PPAR{alpha} is decreased. This coordinated reciprocal regulation of the two transcription factors is key to nutritional regulation of fatty acids and triglycerides as energy storage system and implicates the presence of a cross-talk between these factors. The involvement of LXRs and PPARs in multiple and diverse cellular functions on the nutritional regulation of fatty acid metabolism suggests that these receptors may be integrated with other cellular signaling pathways, in addition to the well-characterized RXR pathway. Indeed, the reciprocal modulation of thyroid hormone and peroxisome proliferator-responsive genes through cross-talk between thyroid hormone receptors (TRs) and PPARs has been demonstrated (46, 47). Moreover, it is reported that LXR{alpha} interacts with PPAR{alpha} and inhibits peroxisome proliferator signaling (48).

In the current study, we analyzed effects of PPARs on the LXR-SREBP-1c system. The results demonstrate that activation of PPAR{alpha} represses LXR signaling through reduction of LXR/RXR heterodimerization in the liver. Taken together with the accompanying paper (49) describing LXR suppression of the PPAR{alpha} signaling, we propose a novel aspect of nutritional regulation with these mutual interactions forming a network of transcription factors regulating fatty acid metabolism.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
PPARs Suppress SREBP-1c Promoter Activity through LXR Response Elements (LXREs)
The SREBP-1c promoter contains two LXREs and is activated by overexpression of LXR{alpha}, ß, and/or addition of an LXR agonist, 22(R)-hydroxycholesterol (22RHC) (Fig. 1Go) as previously reported (29). As shown in luciferase (Luc) reporter gene assays (Fig. 1Go), this LXR activation of SREBP-1c promoter (2.6 kb) is efficiently suppressed by cotransfection of PPAR{alpha} or {gamma}. Even without LXR activation, overexpression of PPAR substantially decreased the basal activity of the SREBP-1c promoter. PPAR inhibition was observed in both HepG2 cells, a liver cell line, and in human embryonic kidney (HEK) 293 cells. HEK293 cells were used for the experiments thereafter. Expression level of transfected PPAR{alpha} or LXR gene in HEK293 cells were roughly comparable to that in mouse liver as estimated by Northern blotting, and thus was within a physiological range (data not shown). To locate cis-element(s) responsible for this inhibitory effect in the SREBP-1c promoter, sequential deletion constructs of SREBP-1c promoter-Luc were estimated in light of PPAR repression of LXR activation (Fig. 2Go). The inhibitory effect of PPAR on both basal and LXR{alpha}-induced activity was partially impaired by deletion of upstream LXRE (LXREa) of the two LXR binding sites and was completely abolished in the absence of both LXREs (LXREa and b). These results suggest that PPAR overexpression cancels out LXR activation of the SREBP-1c promoter through the two LXREs.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 1. PPARs Suppress SREBP-1c Promoter Activity in HepG2 and HEK293 Cells

A Luc reporter gene containing the mouse SREBP-1c promoter (2.6 kb); pBP1c2600-Luc was cotransfected in HepG2 (A) and HEK293 (B) cells with pCMV-LXR (0.1 µg), CMV-PPAR{alpha} or {gamma} (0.5 µg) or an empty vector CMV-7 as a control, and pSV-ß-gal as a reference plasmid. 22RHC (10 µM), or ethanol (EtOH) as a control was added to the cells after transfection in medium with 10% fetal bovine serum 24 h before the assay. After incubation, Luc activity was measured and normalized to ß-gal activity. The relative fold change in Luc activity as compared with a mock-transfected control is shown (means ± SD, n = 3).

 


View larger version (16K):
[in this window]
[in a new window]
  		Figure 2. Identification of a PPAR-Suppressive Region in the SREBP-1c Promoter by Deletion Analysis

SREBP-1c promoter Luc reporters of various lengths were constructed (left panel). The HEK293 cells were transfected with each reporter plasmid, pCMV-LXR{alpha}, pCMV-PPAR{alpha}, and reference plasmid, pSV-ß-gal. After incubation, Luc activity was measured and normalized to ß-gal activity. The effect of PPAR{alpha} in each reporter construct without LXR{alpha} coexpression (basal activity) is expressed as normalized Luc activity (means ± SD, n = 3) (middle panel). The data from LXR{alpha} coexpression (0.1 µg pCMV-LXR{alpha}, LXR{alpha}-induced activity) are shown as fold-change relative to mock transfected control (means ± SD, n = 3) (right panel).

 
To further investigate the effects of PPARs on these LXREs in the SREBP-1c promoter, an LXRE enhancer construct (LXRE-Luc) was used. This construct was shown to be activated by LXR{alpha}, or ß, or an LXR ligand in a very similar fashion to the native SREBP-1c promoter Luc. Reflecting the observation from the 2.6-kb SREBP-1c promoter, LXRE-Luc showed a very similar repression pattern by either PPAR{alpha} or {gamma} coexpression (Fig. 3AGo). When either LXREa or b was disrupted by positionall mutation in LXRE-Luc, the inhibitory effect of PPAR was partially impaired. Mutation of both LXREs abolished the PPAR inhibition of LXR activation. Figure 3BGo shows that the LXR (0.1 µg DNA)-induced LXRE-Luc activity is inhibited by PPAR{alpha} and {gamma} overexpression in a dose-dependent manner. Fifty percent inhibition was observed at 0.025 µg DNA of PPAR. We have previously shown that the SREBP-1c promoter contains an SRE, an activation site for SREBPs, mediating an auto-loop activation of the SREBP-1c-lipogenic gene expression system (50). The 90-bp SREBP-1c promoter construct containing the SRE, but not the upstream LXREs was activated by coexpression of nuclear SREBP-1a or -1c, but not by LXR. The activity of this reporter construct was not changed by PPAR{alpha} or {gamma} coexpression (Fig. 3CGo), indicating that PPAR does not affect SREBP activation of the SREBP-1c promoter through SRE.



View larger version (33K):
[in this window]
[in a new window]
  		Figure 3. Inhibitory Effect of PPARs on SREBP-1c Promoter Activity Is Mediated by the LXRE Complex in the SREBP-1c Promoter

A, The LXRE complex containing two LXREs (LXREa and b) was located at -249 to -148 bp in the SREBP-1c promoter as described previously (29 ). The LXRE complex in the SREBP-1c promoter was fused to a luciferase reporter plasmid, which contained a simian virus 40 promoter (pGL2 promoter vector). This enhancer construct [pBP1c(LXRE)-Luc] or the indicated mutant construct was cotransfected into HEK293 cells with pCMV-LXR{alpha}, ß (0.1 µg, each), pCMV-PPAR{alpha}, {gamma} (0.5 µg, each), or an empty vector, CMV-7 as a control and pSV-ß-gal as a reference plasmid. B, Dose-dependent suppression of the LXRE complex enhancer in the SREBP-1c promoter by PPARs. pBP1c(LXRE)-Luc and pSV-ß-gal were cotransfected into HEK293 cells with pCMV-LXR{alpha}, pCMV-PPAR{alpha}, pCMV-PPAR{gamma} or an empty vector, CMV-7 as a control. After the 24-h incubation, Luc activity was measured and normalized to ß-gal activity. The fold change by PPARs in the Luc activity (means ± SD, n = 3) as compared with the LXR{alpha} (0.1 µg)-induced control is shown. C, pBP1c(90b)-Luc, which contained SRE-complex but not LXRE-complex, was cotransfected into HEK293 cells with pCMV-SREBP-1a, pCMV-SREBP-1c, pCMV-LXR{alpha}, or an empty vector, CMV-7 in the presence or absence of pCMV-PPAR{alpha}, or pCMV-PPAR{gamma} as a control and pSV-ß-gal as a reference plasmid. 22RHC (10 µM), or ethanol (EtOH) as a control was added to the cells after transfection in medium with 10% fetal bovine serum 24 h before the assay. After incubation, Luc activity was measured and normalized by ß-gal activity. The fold change by LXRs or their ligands in the Luc activity (means ± SD, n = 3) as compared with the respective control is shown.

 
PPAR Agonists Enhance PPARs Repression of SREBP-1c Promoter Activity
Activities of PPARs are usually thought to depend upon the presence of PPAR agonists. We estimated the effects of pharmacological PPAR agonists on PPAR inhibition of LXRE-Luc. We used Wy14,643 (Wy), a specific agonist for PPAR{alpha}, and pioglitazone (Pio) for PPAR{gamma}. Their specific actions on PPRE-Luc were shown in Fig. 4Go, B and D. The suppression of LXRE-Luc activity was enhanced by addition of each PPAR specific agonist in a dose-dependent manner (Fig. 4Go, A and C). Without overexpression of PPARs, PPAR{alpha} and {gamma} agonists had no effect on LXRE-Luc activity induced by LXR{alpha} activation (Fig. 4EGo). As was expected, PPAR{alpha} and {gamma} agonists did not influence PPRE-Luc activity without overexpression of PPAR{alpha} and {gamma}, respectively (Fig. 4FGo). These results are presumably due to lack of endogenous PPAR expression in HEK293 cells (data not shown).



View larger version (24K):
[in this window]
[in a new window]
  		Figure 4. Suppression of the SREBP-1c Promoter (LXRE Complex Luc) Activity by PPAR Ligand-Activation of PPARs

Activation of BP1c(LXRE)-Luc by LXR was competed with ligand activation of PPAR{alpha} (A) or PPAR{gamma} (C). Ligand-specific activation of PPAR{alpha} (B) or PPAR{gamma} (D) was confirmed by PPRE-Luc. Effects of ligands in the absence of receptor cotransfection on BP1c(LXRE)-Luc (E) and PPRE-Luc (F) were also estimated. A, pBP1c(LXRE)-Luc (0.25 µg) was cotransfected into HEK293 cells with pCMV-LXR{alpha} (0.1 µg), pCMV-PPAR{alpha} (0.05 µg), and pSV-ß-gal (0.25 µg) as a reference plasmid. A PPAR{alpha} pharmacological ligand; Wy (1, 10, 100 µM), a PPAR{gamma} pharmacological ligand; Pio (1, 10, 100 µM), or DMSO was added to the cells after transfection. B, pPPRE-Luc (0.25 µg) was cotransfected into HEK293 cells with pCMV-PPAR{alpha} (0.01 µg), and pSV-ß-gal (0.25 µg). Wy (10 µM), Pio (10 µM), or DMSO was added to the cells without 22RHC after transfection. C, pBP1c(LXRE)-Luc (0.25 µg) was cotransfected into HEK293 cells with pCMV-LXR{alpha} (0.1 µg), pCMV-PPAR{gamma} (0.05 µg), and pSV-ß-gal (0.25 µg). Wy (1, 10, 100 µM), Pio (1, 10, 100 µM), or DMSO was added to the cells without 22RHC after transfection. D, pPPRE-Luc (0.25 µg) (0.01 µg), and pSV-ß-gal (0.25 µg). Wy (10 µM), Pio (1 µM), or DMSO was added to the cells without 22RHC after transfection. E, pBP1c(LXRE)-Luc (0.25 µg) and pSV-ß-gal (0.25 µg) were cotransfected into HEK293 cells without pCMV-LXR{alpha}. Wy (10 µM), Pio (1 µM), or DMSO (and/or ethanol) was added to the cells with or without 22RHC (10 µM) after transfection. F, pPPRE-Luc (0.25 µg) and pSV-ß-gal (0.25 µg) were cotransfected into HEK293 cells without pCMV-LXR{alpha} and pCMV-PPAR{alpha} or {gamma}. Wy (10 µM), Pio (1 µM), or DMSO (and/or ethanol) was added to the cells with or without 22RHC (10 µM) after transfection. After incubation for 24 h, Luc activity (means ± SD, n = 3) was measured and normalized to ß-gal activity.

 
To examine this suppressive action with endogenous nuclear receptors, we performed reporter assay using rat primary hepatocytes. An LXR ligand, T0901317 highly induced LXRE luciferase activity in these cells. Wy dose dependently suppressed this induced activity (Fig. 5AGo). Thus, PPAR{alpha} interference of the LXR{alpha}-SREBP-1c pathway could be observed under physiological expression levels of these receptors. Meanwhile, Wy alone slightly increased basal LXRE Luc activity, presumably due to a slight induction of endogenous LXR{alpha} expression, to lesser extent, but consistent with previous reports in macrophages (51, 52, 53). We also examined the reciprocal effects of the PPAR ligand with a dual reporter system using SREBP-1c(LXRE)-renilla and PPRE-firefly luciferases in the same setting of HEK 293 cells. After transfection of both PPAR{alpha} and LXR{alpha}, addition of Wy increased PPRE-firefly Luc activity and simultaneously decreased BP1c(LXRE)-renilla Luc activity (Fig. 5Go, B and C). Conversely, addition of T0901713 increased SREBP1c(LXRE) renilla and decreased PPRE-firefly. These results from dual reporter system confirmed consistency of the data from individual reporter system, providing further evidence for the possibility of cross-talk between PPAR and LXR signaling in the cultured cells [see the accompanying paper (49)].



View larger version (20K):
[in this window]
[in a new window]
  		Figure 5. Effect of PPAR{alpha} Ligand on the SREBP-1c Promoter (LXRE Complex Luc) Activity in Rat Primary Hepatocytes (A) and on Dual Reporter Assays for LXRE (B) and PPRE (C) in HEK293 Cells

A, Reporter plasmid, pBP1c(LXRE)-firefly Luc, and reference plasmid, pSV-renilla Luc, were transfected into rat primary hepatocytes. T0901317 and/or Wy were added to the cells after transfection of pBP1c(LXRE)-Luc and pSV-renilla Luc 24 h prior to the assay. After incubation, firefly Luc activity was measured and normalized to renilla Luc activity. B and C, Dual reporters assay was performed with pBP1c(LXRE)-renilla Luc, pACO-PPRE firefly Luc, and pSV-ß-gal that were cotransfected into HEK293 cells with pCMV-LXR{alpha} (0.25 µg) and/or pCMV-PPAR{alpha} (0.25 µg). The cells were cultured with T0901317 or Wy for 24 h after transfection. After incubation, firefly and renilla Luc activities were measured and normalized to ß-gal activity. The fold change by their ligands in the Luc activity (means ± SD, n = 3) as compared with the control is shown.

 
Because PPARs and LXR share RXR as an obligate heterodimer partner, it is conceivable that PPAR repression of LXR activation on the LXRE-containing promoter is mediated through reduction of LXR/RXR heterodimers when RXR levels are limiting. To explore this possibility, the effect of RXR overexpression and/or addition to an RXR ligand [9-cis-retinoic acid (9CRA)] was estimated (Fig. 6Go). Under basal conditions of LXRE-Luc without LXR overexpression, coexpression of PPAR{alpha} or {gamma} caused approximately a 50% reduction. This PPAR inhibition was essentially abolished by coexpression of the same amount of RXR. Although LXR{alpha} (0.1 µg) coexpression induced LXRE-Luc activity by 6-fold, the percent inhibition by PPARs was more prominent (65%) than that without LXR overexpression. RXR overexpression also increased LXRE-Luc activity, and dose dependently suppressed PPAR inhibition, although the percent restoration was slightly less than in the absence of LXR overexpression. When an RXR ligand, 9CRA was added, LXRE-Luc was activated robustly because of LXR/RXR activation. Even in this condition, PPAR{alpha} and {gamma} overexpression efficiently suppressed its activity. Overexpression of RXR substantially, although not completely, restored the activity. These data suggested that PPAR inhibition of LXR activated SREBP1c-LXRE-luc is at least partly due to RXR competition.



View larger version (23K):
[in this window]
[in a new window]
  		Figure 6. Inhibitory Effects of PPARs on the SREBP-1c Promoter (LXRE Complex Luc) Activity Are Restored by Overexpression of RXR

pBP1c(LXRE)-Luc was cotransfected into HEK293 cells with pCMV-LXR{alpha} (0.1 µg), PPAR{alpha} (0.01 µg), PPAR{gamma} (0.01 µg), pCMV-RXR (0.02, 0.1, and 0.5 µg), and pSV-ß-gal as a reference plasmid. 9CRA (10 µM) was added to the cells after transfection. After incubation for 24 h, Luc activity was measured and normalized by ß-gal activity. The percent inhibition of Luc activity by PPAR{alpha} or {gamma} (0.5 µg) as compared with the mock, LXR{alpha} (0.1 µg)-, or 9CRA (10 µM)-induced controls is shown (means ± SD, n = 3). The number in parentheses indicates the fold induction by LXR{alpha} (0.1 µg) or 9CRA (10 µM) in Luc activity as compared with basal BP1c(LXRE)-Luc activity.

 
RXR competition as possible mechanism for PPAR inhibition of LXR signaling prompted us to study the effects of TR and farnesoid X receptor (FXR), other RXR heterodimer partners. Whereas each nuclear receptor was active for luciferase reporter containing its own target cis-element (Fig. 7AGo), PPAR{alpha} was the most effective at inhibiting LXR induced-SREBP1c promoter activity (Fig. 7BGo), highlighting the importance of the cross-talk between PPAR {alpha} and LXR. TRß has some inhibitory effect. Inhibition by FXR was barely detectable. Although recruitment of coactivators is important for activation of receptors (54) including PPARs, overexpression of neither cAMP response element binding protein-binding protein (CBP) nor p300 (data not shown) restored PPAR{alpha} suppression of LXR{alpha}-induced LXRE-Luc activity (Fig. 7CGo).



View larger version (38K):
[in this window]
[in a new window]
  		Figure 7. Effects of RXR Heterodimers and CBP/p300 on SREBP-1c Promoter Activity

HEK293 were grown at 37 C in an atmosphere of 5% CO2 in DMEM supplemented with 10% FBS. Transfection studies were carried out with cells plated on 12-well plates. A, pPPRE-Luc [(ACO-PPRE)3-TK-Luc], pLXRE-Luc (BP1c-LXREb-Luc), pTRE-Luc [(DR4)2-Ld40-Luc], or FXRE-Luc (human ileal bile acid-binding protein promoter-Luc (-862/+ 30-Luc, relative translation start site) and pSV-renilla Luc were cotransfected into HEK293 cells with indicated expression plasmids (0.25 µg): pCMV-LXR{alpha}, pCMV-LXRß, pCMV-PPAR{alpha}, pCMV7-TRß, pCMV-FXR, and/or pCMV-RXR{alpha} (0.25 µg). After incubation for 24 h, Luc activity was measured and normalized to renilla Luc activity. B, pBP1c(LXRE)-Luc and pSV-renilla Luc were cotransfected into HEK293 cells with indicated expression CMV-promoter plasmid (0.25 µg). C, pBP1c(LXRE)-Luc and pSV-renilla Luc were cotransfected into HEK293 cells with indicated expression plasmids; pCMV-LXR{alpha} (0.25 µg), pCMV-PPAR{alpha} (0.25 µg), pCMV-RXR{alpha} (0.5 µg), pCMV-CBP (0.5 µg), and pCMV-p300 (0.5 µg). Cells were treated with or without 3 µM Wy. After incubation for 24 h, Luc activity was measured and normalized to renilla Luc activity. The fold change in the Luc activity as compared with the control is shown (means ± SD, n = 3).

 
PPARs Inhibit LXR{alpha}/RXR Binding to LXRE of SREBP-1c Promoter
The PPAR inhibition of LXR activation observed in reporter assays was also evaluated in gel mobility shift assays (Fig. 8Go). The LXRE DNA probe from the SREBP-1c promoter was shifted by coincubation with recombinant LXR and RXR. This LXR/RXR binding to LXRE was specific and required RXR because none of LXRs alone, PPAR{alpha}/RXR, nor PPAR{alpha}/LXR bound LXRE (Fig. 8AGo). Figure 8BGo shows that addition of PPAR{alpha} or {gamma} to the incubation diminished the shifted signal in a dose-dependent manner. A 4-fold increase in amount of PPAR compared with LXR nearly abolished the shifted signal. Addition of PPAR agonists (fenofibrate, Wy, or Pio) essentially did not change LXR/RXR binding to LXRE without PPAR{alpha} or {gamma}. However, these ligands slightly enhanced the inhibitory effect of PPAR on the binding of LXR to LXRE. As shown in Fig. 8CGo, supplementation with RXR, did not change the basal binding of LXR/RXR to the LXRE, suggesting that the amount of RXR added in the basal condition of this assay was sufficient to form an LXR/RXR heterodimer. The decreased LXR/RXR binding to the LXRE by PPAR was completely restored by further addition of RXR. The data suggest that PPAR suppression of LXR-activated SREBP-1c promoter, as observed in the reporter assays, was mediated through inhibiting LXR/RXR binding to the LXRE, which was presumably caused by reduction of LXR/RXR heterodimer formation.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 8. PPARs Inhibit LXR/RXR Binding to LXREs in the SREBP1c-Promoter in Gel Mobility Shift Assay

A, PPAR/RXR or PPAR/LXR had no ability to bind to LXRE. 32P-labeled LXREb in the SREBP-1c promoter was incubated with in vitro synthesized LXR{alpha}, PPAR{alpha}, and/or RXR{alpha} (1.5 µl of programmed reticulocyte lysate) as indicated for 30 min on ice. The DNA-protein complexes were resolved on a 4.6% PAGE. B, PPARs and their activators inhibited LXR/RXR binding to LXRE. Complexes of LXR/RXR-LXREb were incubated with 2- or 4-fold higher amounts of PPAR{alpha} or PPAR{gamma} in the absence or presence of fenofibric acid (Feno, 100 µM), Wy (100 µM), or Pio (10 µM). C, PPAR{alpha} or PPAR{gamma} inhibition of LXR/RXR binding to LXREb as observed in panel B was restored by addition of a 4-fold higher amount of RXR.

 
PPAR{alpha} Activation Represses LXR Agonist-Induced SREBP-1c Expression
To further evaluate the in vivo physiological significance of PPAR{alpha} interference with LXR signaling, we studied hepatic gene expression in mice treated with the PPAR{alpha} ligand and/or the LXR ligand. The mice were fasted to induce hepatic endogenous PPAR{alpha}. The activation of LXR by T0901317 was confirmed by observational increases in SREBP-1 and ATP-binding cassette transporter A1 (ABCA1) mRNA levels, both of which are well-known LXR target genes. Wy alone minimally increased basal ABCA1 mRNA, which is consistent with reports of PPAR-LXR-ABCA1 pathway (51, 52). The hepatic mRNA levels of ABCA1 and SREBP1 induced by the LXR ligand was suppressed by Wy (Fig. 9AGo). Coimmunoprecipitation experiments were performed to estimate LXR{alpha}/RXR heterodimers in hepatic nuclear extracts. As a control experiment, LXR{alpha} antibody was shown to coimmunoprecipitate successfully the in vitro translated LXR{alpha}/RXR proteins as detected by RXR antibody (Fig. 9BGo). These assays demonstrated that the appreciable increase in amount of LXR{alpha}/RXR heterodimers in hepatic nuclear extracts that was observed in the mice treated with T0901317 was completely suppressed by concomitant Wy treatment (Fig. 9CGo). These results suggest that PPAR{alpha} agonist could cancel hepatic LXR ligand-induced SREBP-1c gene induction via reduction of nuclear LXR/RXR formation. We confirmed that PPAR{alpha}/RXR complex formation was enhanced by PPAR{alpha} agonist using coimmunoprecipitation of in vitro transcription/translation protein (Fig. 9DGo), as was previously reported (41). Effects of ligand activation of PPAR{alpha} on LXR/RXR binding to LXRE was also assessed by gel mobility shift assays using hepatic nuclear extracts from fasted mice as physiological receptors. As shown in Fig. 9EGo, the signal was enhanced by T0901317, and this induction was canceled by further addition of Wy. Studies with receptor antibodies and T0901317 indicated that shifted band of LXRE probe incubated with nuclear extracts was mainly caused by LXR (Fig. 9EGo), although the complex contain some other proteins. The data also suggest that the PPAR{alpha} agonist inhibits LXR ligand-induced LXR/RXR binding to LXRE in a competitive manner.



View larger version (38K):
[in this window]
[in a new window]
  		Figure 9. Inhibition by PPAR{alpha} Ligand of Gene Induction of LXR Target Genes in Mouse Livers (A), LXR Ligand-Induced LXR/RXR Heterodimer Formation (B and C), and Binding to LXRE (D)

A, Mice (n = 3) were fasted and treated with T0901317 (T, 50 mg/kg), Wy (50 mg/kg), or both agonists for 18 h. Total RNA was isolated from the livers of mice and subjected to Northern blot analysis with the indicated cDNA probes. Fold increases of expression relative to corresponding with vehicle-treated controls are shown. Data are means ± SEM. The statistical significance of differences between T0901317-treated and both T0901317- and Wy-treated mice was assessed with the Sheffé test. B, Confirmation of immunoprecipitation of LXR{alpha}/RXR{alpha} heterodimer by anti-LXR{alpha} antibody. In vitro translated RXR{alpha} and LXR{alpha} proteins were incubated with or without T0901317, and the reaction mixtures were incubated with anti-LXR{alpha} antibody (H-144 sc-13068, Santa Cruz Biotechnology, Inc.), followed by binding to protein G-sepharose. The precipitations were washed and subjected to immunoblotting with an anti-RXR{alpha} antibody (D-20, sc-553, Santa Cruz Biotechnology, Inc.). C, Wy inhibited T0901317-induced LXR/RXR{alpha} heterodimer formation in the liver from C57BL6 mice. Mice were fasted and treated with T0901317 (50 mg/kg), Wy (50 mg/kg), or both agonists for 18 h. Hepatic nuclear extracts were prepared from each group. Nuclear extracts (equalized by protein concentrations) were subjected to immunoprecipitation using anti-LXR{alpha} antibody (H-144 sc-13068, Santa Cruz Biotechnology, Inc.) coupled to protein G-sepharose beads. Immunoprecipitates were subjected to SDS-PAGE, and immunoblotted with an anti-RXR{alpha} antibody (D-20 sc-553, Santa Cruz Biotechnology, Inc.). Arrowheads represent the RXR{alpha} or IgG signal. D, Wy potentiates PPAR{alpha} binding to RXR{alpha}. Coimmunoprecipitation of unlabeled RXR{alpha} and 35S-labeled PPAR{alpha} with an anti-RXR{alpha} antibody in the absence or presence of Wy. After immunoprecipitation with protein G-sepharose beads, samples were run on SDS-PAGE. T0901317 induced LXR/RXR{alpha} binding to LXRE was inhibited by addition of Wy. 32P-labeled SREBP1c-LXRE probe and hepatic nuclear extracts from fasted mice were incubated with T0901317 and/or Wy. The DNA-protein complexes were resolved on a 4.6% PAGE. E, T0901317 induced-proteins/LXRE complexes were reduced by an anti-LXR{alpha} antibody (H-144 sc-13068, Santa Cruz Biotechnology, Inc.) or anti-RXR{alpha} antibody (D-20 sc-553, Santa Cruz Biotechnology, Inc.). 32P-labeled SREBP1c-LXRE probe and hepatic nuclear extracts (1 µg) from fasted mice were incubated with 20 µl buffer (buffer A) containing 10 mM HEPES (pH 7.6), 50 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl2, 8.5% glycerol, 1 mM dithiothreitol, 0.1% Triton X-100, and 1 mg/ml nonfat milk for 1 h on ice. The DNA-protein complexes were resolved in a 4.6% PAGE.

 
The observational inhibition of SREBP-1c gene expression by PPAR{alpha} activation in transfection studies and mouse livers was also estimated in rat primary hepatocytes. As evaluated by Northern blot analysis, the hepatocytes showed consistent PPAR{alpha} activation by Wy (Fig. 10AGo). Addition of Wy to the medium caused dose-dependent increases in PPAR{alpha} target gene, mHMG-CoA synthase, and acyl-CoA oxidase (ACO). LXR{alpha} expression was induced as previously described (51, 52, 53) but only modestly. PPAR{alpha} gene was also significantly induced by Wy owing to autoregulation as was recently described (55). As shown in Fig. 10BGo, when the cells were incubated with T0901317, SREBP-1c expression was robustly induced through LXR activation. This induction was suppressed in a dose-dependent manner by coincubation with Wy (Fig. 10BGo). The inhibitory effect of Wy was also observed with cycloheximide treatment, suggesting that this action might be independent of de novo protein synthesis (Fig. 10CGo). These data suggest that suppression of the LXR-SREBP1c pathway by the PPAR{alpha} ligand is mediated through its PPAR{alpha} activation and is more prominent under conditions of LXR activation.



View larger version (58K):
[in this window]
[in a new window]
  		Figure 10. Ligand-Activation of PPAR{alpha} Suppresses LXR Ligand Induced-SREBP1 Gene Expression in Primary Rat Hepatocytes

A, Wy induced gene expression of mHMG-CoA Syn, ACO, SREBP-1, PPAR{alpha}, and LXR{alpha}. Rat primary hepatoctyes were prepared as described in Materials and Methods. The cells were incubated with the indicated concentration of Wy for 24 h. B, Wy suppressed induction of SREBP-1 gene expression by T0901317 (T) treatment. The hepatocytes were incubated with the indicated concentration of T0901317 in the absence or presence of Wy for 24 h. C, Cycloheximide had no effect in the inhibition of Wy on T0901317 induced-SREBP-1 gene expression. Total RNA was extracted and Northern blot analysis was performed with the indicated cDNA probes. Fold changes of expression relative to corresponding with vehicle-treated controls are shown.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
MATERIALS AND METHODS
 REFERENCES
 
The current studies demonstrate that PPAR{alpha} activation suppresses LXR-mediated SREBP-1c gene expression. Evidence for this was first shown in luciferase assays in cultured cells and was confirmed in rat primary hepatocyte cultures and mouse livers. Overexpression of PPARs represses LXR/RXR activation of LXRE containing promoters such as the SREBP-1c promoter. This inhibitory effect was enhanced by addition of PPAR ligands. In the liver nuclei, addition of PPAR{alpha} agonist enhanced binding of PPAR{alpha} to RXR, decreased the amount of LXR/RXR heterodimers, leading to suppression of LXR ligand-activated SREBP-1c expression. RXR supplementation experiments suggest that the mechanism for PPAR inhibition of LXR/RXR activity could be at least partly RXR competition between PPAR and LXR. Involvement of RXR competition in the regulation of activities of nuclear receptors has been well established for PPAR and TR (46, 47, 56). It has been also reported that LXR{alpha} interacts with PPAR{alpha} and inhibits peroxisome proliferator signaling (48). As described in the accompanying paper (49), PPAR{alpha} heterodimerizes with both LXR{alpha} and ß as efficiently as with RXR. Because PPAR{alpha}/LXR{alpha} (ß) cannot bind to LXRE, this complex formation could interfere with the formation of LXR{alpha}/RXR and activation of LXRE containing promoters by LXR{alpha}/RXR. Therefore, as schematized in Fig. 11Go, it is possible that abundant PPAR{alpha} can absorb LXR as well as RXR, resulting in inhibition of LXR/RXR formation and SREBP-1c promoter activation. Reduction of hepatic nuclear LXR/RXR from fasted mice doubly treated with LXR and PPAR{alpha} ligands supports this hypothesis. Whether the dominant mechanism for PPAR inhibition of SREBP-1c expression is RXR competition between PPAR and LXR, or LXR competition between PPAR{alpha} and RXR is currently unknown. The amounts of three nuclear receptor proteins in the nucleus, concentration of each ligand, and affinity for one another, possible involvement of other nuclear receptors and cofactors will all be involved in determining the overall effect. Further studies will be needed to determine the precise mutual interactions in other combinations of nuclear receptors.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 11. Mechanism by which PPAR Suppresses the SREBP-1c Promoter Activity through Interfering with LXR-RXR.

1, LXR/RXR has been shown to bind and activate LXREs in the SREBP-1c promoter. 2, Reciprocally, PPAR{alpha}/RXR activates gene expression crucial for lipid degradation through PPREs. 3 and 4, The current study proposes interference of LXR/RXR signaling by PPAR/RXR and PPAR/LXR. 5, PUFA (polyunsaturated fatty acid), representative PPAR{alpha} ligands, can suppress LXR activation independently of PPAR{alpha} (59 64 ). The accompanying paper (49 ) describes LXR suppress PPAR{alpha}-targeted gene expression crucial for lipid catabolism by inhibiting PPAR-RXR binding to the PPRE [see Fig. 12 of the accompanying paper (49 )].

 
LXR{alpha} expression was recently shown to be regulated by PPAR (51, 52, 53). PPAR enhances cholesterol efflux in macrophages via PPAR-LXR{alpha}-ABCA1 pathway, and a combination treatment with both PPAR and LXR agonists result in a further induction in ABCA1 mRNA in macrophages (51, 52). We also observed a relatively small PPAR{alpha} ligand-gene induction of LXR. We propose that the PPAR-LXR{alpha}-ABCA1 pathway has been established in macrophages, PPAR-LXR-SREBP1c pathway may not be very potent in liver. Lack of hepatic SREBP-1c induction after adenoviral overexpression of PPAR{gamma} supports this (57). Each receptor, ligand, and cofactor concentration could be important for this tissue specificity of cross-talk of transcription factors.

The physiological relevance of the cross-talk between PPAR{alpha} and LXR could be extended to nutritional regulation of energy metabolism by a mutual interaction between PPAR{alpha} and SREBP-1c, whose expression are dominated by LXR. Hepatic fatty acid degradation is activated in an energy-depleted state such as fasting to produce alternate energy substrates such as ketone bodies. PPAR{alpha} activation plays a key role in this adaptic gene induction (44, 45). As has been shown for other nuclear receptors, PPAR{alpha} activation requires binding of its ligands, one of which could be polyunsaturated fatty acids, presumably lipolyzed from adipose tissues. More importantly, we (12) and other group (44) have shown that hepatic PPAR{alpha} expression is nutritionally regulated. Hepatic PPAR{alpha} level is induced by fasting and suppressed by refeeding. This nutritional regulation of PPAR{alpha} expression suggests that changes in the amount of PPAR protein could also control its downstream genes of lipid oxidation as well as changes in the ligand concentration. In a fasted state, lipogenesis should be declined in a coordinated fashion with activation of fatty acid degradation. Marked induction of PPAR{alpha} in the livers of fasted mice might play a role in an efficient suppression of lipogenic genes by inhibition of SREBP-1c gene expression through a mechanism that is proposed in the current study. Consistently, it has recently been reported that PPAR{alpha}-null mice show dysregulation of hepatic lipogenic genes (58). Polyunsaturated fatty acid could contribute to this reciprocal energy regulation by PPAR{alpha} and SREBP-1c through activation of PPAR{alpha} ligands and direct inhibition of SREBP-1c as recently reported (59).

In the current study, we also observed similar inhibitory effect by overexpression of PPAR{gamma} on SREBP-1c expression. In a regular nutritional state, PPAR{gamma} expression is extremely low in the liver, and contribution of PPAR{gamma} expression to hepatic regulation of SREBP-1c is unlikely. In contrast, PPAR{gamma} is highly induced and involved in adipogenesis. Previous reports suggest that the role of adipocyte determination and differentiation 1 (ADD1)/SREBP-1c in the adipose tissue is positioned upstream of PPAR{gamma} activation through two different mechanisms: ligand production (60) and direct induction (61). PPAR{gamma} has recently been reported to activate LXR{alpha} gene expression (52), which could in turn activate SREBP-1c gene expression, leading to a speculation that these three factors could form an auto-loop activation in adipogenesis. PPAR{gamma} inhibition of SREBP-1c in the current study could antagonize this potential auto-loop and be involved in the complex transcriptional cross-talk among PPAR{gamma}, SREBP-1c, and LXR in the adipocytes.

Taken together with the accompanying paper (49) showing LXR inhibition of PPAR{alpha} signaling, we show the mutual interaction between PPAR{alpha} and LXRs in the reciprocal regulation of PPAR{alpha} and SREBP-1c target genes. The data suggest that cross-talk of these nuclear factors could play crucial roles in nutritional regulation of fatty acid metabolism (see Fig. 11Go). However, as recent studies show that there could be a global and complex network of nutritional transcriptional factors, further studies are needed to evaluate the physiological relevance of the cross-talk between these and other nuclear transcription factors.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
REFERENCES
 
Materials
Anti-RXR{alpha} (D-20, sc-553) and LXR{alpha} (H-144, sc-13068) antibody were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), 22RHC, 9CRA, and Wy were purchased from Sigma (St. Louis, MO), Redivue [{alpha}-32P]deoxy-CTP (6000 Ci/mmol) from Amersham Biosciences Inc. (Amersham, Buckinghamshire, UK), and restriction enzymes from New England Biolabs (Boston, MA). Fenofibric acid and Pio were provided by Laboratories Fournier (Paris, France), and Takeda Pharmaceutical (Osaka, Japan), respectively.

Plasmid
Luc gene constructs containing a 2.6-kb fragment of the mouse SREBP-1c promoter (pBP1c2600-Luc), other SREBP-1c promoter luciferase constructs, and expression plasmids, pCMV (cytomegalovirus)-mLXR{alpha} and pCMV-mLXRß were prepared as previously described (29). Expression plasmids, pCMV-PPAR{alpha} and pCMV-PPAR{gamma} were prepared by subcloning PCR products from mouse liver cDNA into CMV-7. CMV-T7 promoter expression plasmid of human RXR{alpha} (pCMV-RXR) was a kind gift from Dr. D. J. Mangelsdorf (University of Texas Southwestern Medical Center, Dallas, TX). pCMV-FXR, pCMX-TRß, and pCMV-CBP were from Dr. H. Fujii (Graduate School of Agricultural and Life Science, The University of Tokyo, Tokyo, Japan), Dr. R. M. Evans (The Salk Institute for Biological Studies, La Jolla, CA), and Dr. T. Nakajima (St. Marianna University School of Medicine, Kawasaki, Japan), respectively.

Transfections and Luciferase Assays
HEK293 and HepG2 cells were grown at 37 C in an atmosphere of 5% CO2 in DMEM containing 25 mM glucose, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate supplemented with 10% fetal bovine serum (FBS). Transfection studies were carried out with cells plated on 12-well plates as previously described (50). The indicated amount of each expression plasmid was transfected simultaneously with a Luc reporter plasmid (0.25 µg) and pSV (simian virus 40)-ß-galactosidase (ß-gal) (0.2–0.4 µg) or pSV-renilla Luc (0.05 µg). The total amount of DNA in each transfection was adjusted to 1.5 µg/well with pCMV7. 22RHC was dissolved in ethanol and PPAR ligands in dimethylsulfoxide (DMSO). Each agent was added to the cells immediately after transfection in DMEM with 10% FBS, and incubated for 24 h. After incubation, the amount of Luc activity in transfectants was measured and normalized to the amount of ß-gal or renilla Luc activity as measured by standard kits (Promega, Madison, WI). pBP1c(LXRE)-firefly Luc (1.5 µg) and pSV-renilla Luc (0.5 µg) were transfected into rat primary hepatocytes by using lipofectin reagent (Invitrogen). After incubation for 24 h, the amount of firefly Luc activity in transfectants was measured and normalized to the amount of renilla Luc activity. Dual reporter assay was performed with pBP1c(LXRE)-firefly Luc (0.25 µg), PPRE-renilla Luc (0.25 µg), and pSV-ß-gal (0.2 µg).

Gel Mobility Shift Assays
Gel mobility shift assays were performed as previously described (29). Briefly, the entire open reading frames of mouse (m) LXR{alpha} and mPPAR{alpha} were amplified from the pCMV-LXR{alpha} and pCMV-mPPAR{alpha} by PCR (forward primers, 5'-TTGGTAATGTCCAGGG and 5'-GCCATACACTTGAGTGACAAT; reverse primers, 5'-CTTCCAAGGCCAGGAGA and 5'-AGATCAGTACATGTCTCTGTAGA) and cloned into the EcoRI and NotI sites, and SalI and NotI sites of the pBluescript II SK plasmid, respectively. mLXR{alpha}, mPPAR{alpha}, and human (h) RXR proteins were generated from the expression vectors using a coupled in vitro transcription/translation system (Promega). Double-stranded oligonucleotides used in gel shift assays were prepared by annealing both strands of the LXREb in the LXRE complex of the SREBP-1c promoter (29). These were then labeled with [{alpha}-32P]deoxy-CTP by Klenow enzyme, followed by purification on Sephadex G50 columns. The labeled probes (30,000–100,000 cpm) were incubated with nuclear receptor lysates (1–1.5 µl) or hepatic nuclear extract (1 µg) in a mixture (20 µl) containing 10 mM Tris-HCl, pH 7.6; 50 mM KCl; 0.05 mM EDTA; 2.5 mM MgCl2; 8.5% glycerol; 1 mM dithiothreitol; 0.5 µg/ml poly (deoxyinosine-deoxycytidine), 0.1% Triton X-100; and 1 mg/ml nonfat milk for 30 min on ice. The DNA-protein complexes were resolved on a 4.6% PAGE at 140 V for 1 h at 4 C. Gel were dried and exposed to BAS2000 filters with BAStation software (Fuji Photo Film, Kanagawa, Japan).

Animals
Male mice (C57BL/6J) were obtained from Charles River Japan (Yokohama, Japan). All mice were given a standard diet and tap water ad libitum. All institutional guidelines for animal care and use were applied in this study. Vehicle (0.5% carboxymethyl-cellulose) T0901317 (50 mg/kg), Wy (50 mg/kg), or both their agonists was orally administered to the mice before 18 h fasting. For fasting and refeeding treatment, mice were fasted for 24 h and fed a high sucrose/fat free diet for 12 h as described (13). Hepatic nuclear extracts was prepared from the livers as previously described (62).

Coimmunoprecipitation of Receptors
In vitro translated [35S]-methionine-labeled receptors with unlabeled receptors or hepatic nuclear extracts from ligand-treated mice were brought to a final volume of 20 µl with buffer containing 10 mM HEPES (pH 7.6), 50 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl2, 8.5% glycerol, 1 mM dithiothreitol, 0.1% Triton X-100, and 1 mg/ml nonfat milk for 2 h at 4 C and incubated with 10 µl of anti-PPAR{alpha} (H-98 sc-9000, Santa Cruz Biotechnology, Inc.) or anti-LXR{alpha} (H-144 sc-13068, Santa Cruz Biotechnology, Inc.) polyclonal antibody binding to protein G-sepharose for overnight at 4 C. The precipitations were washed with PBS containing 0.2% Tween-20 and 3% BSA. After microcentrifugation, the pellet was washed four times with 1 ml of ice-cold PBS containing 0.2% Tween-20. Twenty microliters of SDS-PAGE sample buffer were added to the final pellet and boiled for 5 min at 95 C. The supernatant was subjected to electrophoresis on 8 or 10% SDS-PAGE.

Hepatocyte Isolation and Culture
Primary hepatocytes were isolated from male Sprague- Dawley rats (160–180 g; Japan Clea, Tokyo, Japan) using the collagenase perfusion method as described previously (63). The viability of isolated cells was over 90% as determined by the trypan blue. Cells were resuspended in DMEM containing 100 U/ml penicillin and 100 µg/ml streptomycin sulfate supplemented with 5% FBS, seeded on collagen-coated dishes 100 mm at a final density of 4 x 104 cells/cm2. After an attachment for 4 h, cells were cultured with medium containing the indicated agonists with or without 5 µM cycloheximide for 24 h.

Northern Blot Analysis
Total RNA was extracted using TRIZOL Reagent (Invitrogen Corp., Carlsbad, CA). Equal aliquots of total RNA from mice in each group were pooled (total 10 µg), subjected to formalin-denatured agarose electrophoresis, and transferred to nylon membrane (Hybond N, Amersham Pharmacia Biotech, Uppsala, Sweden). Blot hybridization was performed with the cDNA probes labeled with [{alpha}-32P]CTP (6000 Ci/mmol) using the Megaprime DNA Labeling System (Amersham Biosciences Inc.). The cDNA probes for SREBP-1, ACO, PPAR{alpha}, LXR{alpha} and ß, ABCA1, and acidic ribosomal phosphoprotein PO (36B4) were prepared as previously described (12, 29). The cDNA probes for mHMG-CoA Syn were provided by Kyorin Pharmaceutical Co. Ltd. (Tochigi, Japan). Each signal was analyzed with BAS2000 and BAStation software (Fuji Photo Film).


   ACKNOWLEDGMENTS
 
We thank M. Nakakuki, Y. Iizuka, S. Tomita, and K. Ohashi for helpful discussion.


   FOOTNOTES
 
This study was supported by the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research.

T.Y. and T.I. equally contributed to this work.

Abbreviations: ABCA1, ATP-binding cassette transporter A1; ACO, acyl-CoA oxidase; 36B4, acidic ribosomal phosphoprotein PO; 9CRA, 9-cis-retinoic acid; CBP, cAMP response element binding protein-binding protein; CMV, cytomegalovirus; CoA, coenzyme A; DMSO, dimethylsulfoxide; FBS, fetal bovine serum; FXR, farnesoid X receptor; ß-gal, ß-galactosidase; HEK, human embryonic kidney; Luc, luciferase; LXR, liver X receptor; LXRE, liver X receptor response element; m, mouse; Pio, pioglitazone; PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator responsive element; pSV, simian virus 40 promoter plasmid; 22RHC, 22(R)-hydroxycholesterol; RXR, retinoid X receptor; SRE, sterol regulatory element; SREBP-1c, sterol regulatory element-binding protein 1c; TK, thymidine kinase; Wy, Wy14,643.

Received for publication May 23, 2002. Accepted for publication April 14, 2003.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Brown MS, Goldstein JL 1997 The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340[CrossRef][Medline]
  2. Brown MS, Goldstein JL 1999 A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96:11041–11048[Abstract/Free Full Text]
  3. Brown MS, Ye J, Rawson RB, Goldstein JL 2000 Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391–398[CrossRef][Medline]
  4. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL 1993 Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem 268:14490–14496[Abstract/Free Full Text]
  5. Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, Towle HC, Spiegelman BM 1995 Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol Cell Biol 15:2582–2588[Abstract]
  6. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS 1993 SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75:187–197[CrossRef][Medline]
  7. Tontonoz P, Kim JB, Graves RA, Spiegelman BM 1993 ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 13:4753–4759[Abstract/Free Full Text]
  8. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X 1993 SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 90:11603–11607[Abstract/Free Full Text]
  9. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS 1997 Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838–845[Medline]
  10. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H 1998 Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 101:2331–2339[Medline]
  11. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL 1996 Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98:1575–1584[Medline]
  12. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N 1999 Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274:35832–35839[Abstract/Free Full Text]
  13. Horton JD, Bashmakov Y, Shimomura I, Shimano H 1998 Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 95:5987–5992[Abstract/Free Full Text]
  14. Yahagi N, Shimano H, Hasty AH, Amemiya-Kudo M, Okazaki H, Tamura Y, Iizuka Y, Shionoiri F, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N 1999 A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 274:35840–35844[Abstract/Free Full Text]
  15. Xu J, Nakamura MT, Cho HP, Clarke SD 1999 Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem 274:23577–23583[Abstract/Free Full Text]
  16. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM 1998 Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101:1–9[Medline]
  17. Kim HJ, Takahashi M, Ezaki O 1999 Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 274:25892–25898[Abstract/Free Full Text]
  18. Osborne TF 2000 Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 275:32379–32382[Free Full Text]
  19. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P 1995 The nuclear receptor superfamily: the second decade. Cell 83:835–839[CrossRef][Medline]
  20. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ 1996 An oxysterol signalling pathway mediated by the nuclear receptor LXR {alpha}. Nature 383:728–731[CrossRef][Medline]
  21. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM 1997 Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272:3137–3140[Abstract/Free Full Text]
  22. Russell DW 1999 Nuclear orphan receptors control cholesterol catabolism. Cell 97:539–542[CrossRef][Medline]
  23. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ 1995 LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9:1033–1045[Abstract/Free Full Text]
  24. Song C, Kokontis JM, Hiipakka RA, Liao S 1994 Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci USA 91:10809–10813[Abstract/Free Full Text]
  25. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ 1998 Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR {alpha}. Cell 93:693–704[CrossRef][Medline]
  26. Luo Y, Tall AR 2000 Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105:513–520[Medline]
  27. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ 2000 Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289:1524–1529[Abstract/Free Full Text]
  28. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ 2000 Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR{alpha} and LXRß. Genes Dev 14:2819–2830[Abstract/Free Full Text]
  29. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura S, Ishibashi S, Yamada N 2001 Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 21:2991–3000[Abstract/Free Full Text]
  30. Schoonjans K, Staels B, Auwerx J 1996 The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93–109[Medline]
  31. Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550[CrossRef][Medline]
  32. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-{alpha}, -ß, and -{gamma} in the adult rat. Endocrinology 137:354–366[Abstract]
  33. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR {gamma} 2, a lipid-activated transcription factor. Cell 79:1147–1156[CrossRef][Medline]
  34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK 1998 The peroxisome proliferator-activated receptor-{gamma} is a negative regulator of macrophage activation. Nature 391:79–82[CrossRef][Medline]
  35. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM 1998 PPAR{gamma} promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252[CrossRef][Medline]
  36. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM 1998 Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR{gamma}. Cell 93:229–240[CrossRef][Medline]
  37. Issemann I, Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650[CrossRef][Medline]
  38. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W 1992 Control of the peroxisomal ß-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879–887[CrossRef][Medline]
  39. Gottlicher M, Widmark E, Li Q, Gustafsson JA 1992 Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653–4657[Abstract/Free Full Text]
  40. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W 1993 Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160–2164[Abstract/Free Full Text]
  41. Forman BM, Chen J, Evans RM 1997 Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94:4312–4317[Abstract/Free Full Text]
  42. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM 1997 Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors {alpha} and {gamma}. Proc Natl Acad Sci USA 94:4318–4323[Abstract/Free Full Text]
  43. Krey G, Braissant O, L’Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W 1997 Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11:779–791[Abstract/Free Full Text]
  44. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W 1999 Peroxisome proliferator-activated receptor {alpha} mediates the adaptive response to fasting. J Clin Invest 103:1489–1498[Medline]
  45. Leone TC, Weinheimer CJ, Kelly DP 1999 A critical role for the peroxisome proliferator-activated receptor alpha (PPAR{alpha}) in the cellular fasting response: the PPAR{alpha}-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96:7473–7478[Abstract/Free Full Text]
  46. Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA 1995 Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. J Biol Chem 270:18117–18122[Abstract/Free Full Text]
  47. Chu R, Madison LD, Lin Y, Kopp P, Rao MS, Jameson JL, Reddy JK 1995 Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding beta-oxidation enzymes: cross talk between peroxisome proliferator and T3 signaling pathways. Proc Natl Acad Sci USA 92:11593–11597[Abstract/Free Full Text]
  48. Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP 1996 The orphan nuclear hormone receptor LXR {alpha} interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling. J Biol Chem 271:9189–9192[Abstract/Free Full Text]
  49. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J-i, Ishibashi S, Yamada N 2003 Cross-talk between peroxisome proliferator-activated receptor (PPAR) {alpha} and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Endocrinology 144:1255–1267[CrossRef]
  50. Amemiya-Kudo M, Shimano H, Yoshikawa T, Yahagi N, Hasty AH, Okazaki H, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N 2000 Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene. J Biol Chem 275:31078–1085[Abstract/Free Full Text]
  51. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B 2001 PPAR-{alpha} and PPAR-{gamma} activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53–58[CrossRef][Medline]
  52. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P 2001 A PPAR {gamma}-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161–171[CrossRef][Medline]
  53. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI 2000 Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-{alpha}. Mol Endocrinol 14:741–752[Abstract/Free Full Text]
  54. McKenna NJ, O’Malley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465–474[CrossRef][Medline]
  55. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B 2002 Characterization of the human PPAR{alpha} promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013–1028[Abstract/Free Full Text]
  56. Hunter J, Kassam A, Winrow CJ, Rachubinski RA, Capone JP 1996 Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes. Mol Cell Endocrinol 116:213–221[CrossRef][Medline]
  57. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK 2003 Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to PPAR{gamma} 1 overexpression. J Biol Chem 278:498–505[Abstract/Free Full Text]
  58. Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF 2001 Disturbances in the normal regulation of SREBP-sensitive genes in PPAR {alpha}-deficient mice. J Lipid Res 42:328–337[Abstract/Free Full Text]
  59. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Takahashi A, Sone H, Osuga Ji J, Gotoda T, Ishibashi S, Yamada N 2002 Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 277:1705–1711[Abstract/Free Full Text]
  60. Kim JB, Wright HM, Wright M, Spiegelman BM 1998 ADD1/SREBP1 activates PPAR{gamma} through the production of endogenous ligand. Proc Natl Acad Sci USA 95:4333–4337[Abstract/Free Full Text]
  61. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J 1999 Regulation of peroxisome proliferator-activated receptor {gamma} expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 19:5495–5503[Abstract/Free Full Text]
  62. Sheng Z, Otani H, Brown MS, Goldstein JL 1995 Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 92:935–938[Abstract/Free Full Text]
  63. Massague J, Guinovart JJ 1977 Insulin control of rat hepatocyte glycogen synthase and phosphorylase in the absence of glucose. FEBS Lett 82:317–320[CrossRef][Medline]
  64. Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, Brown MS 2001 Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 98:6027–6032[Abstract/Free Full Text]

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα  |  PPARγ  |  LXRβ  |  LXRα  |  RXRα
Coregulators:   CBP  |  p300
Ligands:   22α-Hydroxycholesterol  |  T0901317  |  Pirinixic acid  |  9-cis-Retinoic acid



This article has been cited by other articles:


Home page
 Toxicol SciHome page
A. K. Goetz and D. J. Dix
Mode of Action for Reproductive and Hepatic Toxicity Inferred from a Genomic Study of Triazole Antifungals
Toxicol. Sci., August 1, 2009; 110(2): 449 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
H. Basciano, A. Miller, C. Baker, M. Naples, and K. Adeli
LXR{alpha} activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins
Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G323 - G332.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Wang, P. M. Rogers, K. R. Stayrook, C. Su, G. Varga, Q. Shen, S. Nagpal, and T. P. Burris
The Selective Alzheimer's Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene
Mol. Pharmacol., December 1, 2008; 74(6): 1716 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Colin, E. Bourguignon, A.-B. Boullay, J.-J. Tousaint, S. Huet, F. Caira, B. Staels, S. Lestavel, J.-M. A. Lobaccaro, and P. Delerive
Intestine-Specific Regulation of PPAR{alpha} Gene Transcription by Liver X Receptors
Endocrinology, October 1, 2008; 149(10): 5128 - 5135.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wang, P. M. Rogers, C. Su, G. Varga, K. R. Stayrook, and T. P. Burris
Regulation of Cholesterologenesis by the Oxysterol Receptor, LXR{alpha}
J. Biol. Chem., September 26, 2008; 283(39): 26332 - 26339.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Anderson and J. Borlak
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
H. Wang, Y. Zhang, E. Yehuda-Shnaidman, A. V. Medvedev, N. Kumar, K. W. Daniel, J. Robidoux, M. P. Czech, D. J. Mangelsdorf, and S. Collins
Liver X Receptor {alpha} Is a Transcriptional Repressor of the Uncoupling Protein 1 Gene and the Brown Fat Phenotype
Mol. Cell. Biol., April 1, 2008; 28(7): 2187 - 2200.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Gallardo, E. Bonzon-Kulichenko, T. Fernandez-Agullo, E. Molto, S. Gomez-Alonso, P. Blanco, J. M. Carrascosa, M. Ros, and A. Andres
Tissue-Specific Effects of Central Leptin on the Expression of Genes Involved in Lipid Metabolism in Liver and White Adipose Tissue
Endocrinology, December 1, 2007; 148(12): 5604 - 5610.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn
Genomic Profiling in Nuclear Receptor-Mediated Toxicity
Toxicol Pathol, June 1, 2007; 35(4): 474 - 494.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y.-Y. Liu, R. S. Heymann, F. Moatamed, J. J. Schultz, D. Sobel, and G. A. Brent
A Mutant Thyroid Hormone Receptor {alpha} Antagonizes Peroxisome Proliferator-Activated Receptor {alpha} Signaling in Vivo and Impairs Fatty Acid Oxidation
Endocrinology, March 1, 2007; 148(3): 1206 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Penza, C. Montani, A. Romani, P. Vignolini, B. Pampaloni, A. Tanini, M. L. Brandi, P. Alonso-Magdalena, A. Nadal, L. Ottobrini, et al.
Genistein Affects Adipose Tissue Deposition in a Dose-Dependent and Gender-Specific Manner
Endocrinology, December 1, 2006; 147(12): 5740 - 5751.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
R. J Deckelbaum, T. S Worgall, and T. Seo
n-3 Fatty acids and gene expression
Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1520 - 1525S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Y. Zhang, X. Zhang, L. Chen, J. Wu, D. Su, W. J. Lu, M.-T. Hwang, G. Yang, S. Li, M. Wei, et al.
Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule
Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1065 - F1073.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. K. Cheema, A. Agarwal-Mawal, C. M. Murray, and S. Tucker
Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet
J. Lipid Res., November 1, 2005; 46(11): 2356 - 2366.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
C. A Maloney and W. D Rees
Gene-nutrient interactions during fetal development
Reproduction, October 1, 2005; 130(4): 401 - 410.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C. Le May, M. Cauzac, C. Diradourian, D. Perdereau, J. Girard, A.-F. Burnol, and J.-P. Pegorier
Fatty Acids Induce L-CPT I Gene Expression through a PPAR{alpha}-Independent Mechanism in Rat Hepatoma Cells
J. Nutr., October 1, 2005; 135(10): 2313 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. K. Kramer, L. Al-Khalili, S. Perrini, J. Skogsberg, P. Wretenberg, K. Kannisto, H. Wallberg-Henriksson, E. Ehrenborg, J. R. Zierath, and A. Krook
Direct Activation of Glucose Transport in Primary Human Myotubes After Activation of Peroxisome Proliferator-Activated Receptor {delta}
Diabetes, April 1, 2005; 54(4): 1157 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Ide
Interaction of Fish Oil and Conjugated Linoleic Acid in Affecting Hepatic Activity of Lipogenic Enzymes and Gene Expression in Liver and Adipose Tissue
Diabetes, February 1, 2005; 54(2): 412 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
K. R Steffensen, S. Y. Neo, T. M Stulnig, V. B Vega, S. S Rahman, G. U Schuster, J.-A. Gustafsson, and E. T Liu
Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals
J. Mol. Endocrinol., December 1, 2004; 33(3): 609 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. P. Anderson, C. Dunn, A. Laughter, L. Yoon, C. Swanson, T. M. Stulnig, K. R. Steffensen, R. A.S. Chandraratna, J.-A. Gustafsson, and J. C. Corton
Overlapping Transcriptional Programs Regulated by the Nuclear Receptors Peroxisome Proliferator-Activated Receptor {alpha}, Retinoid X Receptor, and Liver X Receptor in Mouse Liver
Mol. Pharmacol., December 1, 2004; 66(6): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
T. Kino and G. P. Chrousos
Combating Atherosclerosis With LXR{alpha} And PPAR{alpha} Agonists: Is Rational Multitargeted Polypharmacy the Future of Therapeutics in Complex Diseases?
Mol. Interv., October 1, 2004; 4(5): 254 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. Paterson, N. M. Morton, C. Fievet, C. J. Kenyon, M. C. Holmes, B. Staels, J. R. Seckl, and J. J. Mullins
Metabolic syndrome without obesity: Hepatic overexpression of 11{beta}-hydroxysteroid dehydrogenase type 1 in transgenic mice
PNAS, May 4, 2004; 101(18): 7088 - 7093.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. S. Ng, C. Xie, G. F. Maguire, X. Zhu, F. Ugwu, E. Lam, and P. W. Connelly
Hypertriglyceridemia in Lecithin-cholesterol Acyltransferase-deficient Mice Is Associated with Hepatic Overproduction of Triglycerides, Increased Lipogenesis, and Improved Glucose Tolerance
J. Biol. Chem., February 27, 2004; 279(9): 7636 - 7642.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat
The Peroxisome Proliferator-Activated Receptor {beta}/{delta} Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells
Mol. Endocrinol., December 1, 2003; 17(12): 2477 - 2493.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshikawa, T.
Right arrow Articles by Yamada, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshikawa, T.
Right arrow Articles by Yamada, N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals